EMN

Business Context and Reporting Period

Company: Eastman Chemical Company
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005
Overview: Eastman reported its best first-quarter results in company history, driven by a turnaround strategy implemented since 2002. Key drivers included the completion of restructuring and divestitures in 2004, increased selling prices to offset rising raw material and energy costs, and improved capacity utilization. The company operates through three divisions: Eastman, Voridian, and Developing Businesses.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 10% ($165 million) year-over-year. This was primarily due to higher selling prices (+$300 million impact) and increased volumes in continuing product lines, which offset volume decreases from divested businesses.
• Profitability Surge: Operating earnings jumped from $15 million to $244 million. This dramatic improvement was fueled by higher gross margins (up 70%) and a significant reduction in asset impairments and restructuring charges (down from $67 million in Q1 2004 to $9 million in Q1 2005).
• Segment Performance:
  • Eastman Division: Operating earnings rose to $138 million from $15 million, driven by the CASPI and PCI segments.
  • Voridian Division: Operating earnings increased to $118 million from $21 million, with the Polymers segment turning a loss of $12 million into earnings of $71 million.
  • Developing Businesses: Remained unprofitable with an operating loss of $21 million.
• Cash Flow: Operating cash flow improved by $136 million to $102 million, reversing the negative cash flow of the prior year.

Guidance, Outlook, and Risks

Management Outlook for 2005

• Earnings: Management expects Q2 2005 earnings per share to be similar to Q1 2005.
• Costs & Pricing: Continued volatility in raw material and energy costs is expected; the company plans to pursue price increases to maintain margins.
• Capital Expenditures: Expected to increase to between $340 million and $360 million, exceeding depreciation and amortization. This includes construction of a new PET facility in South Carolina.
• Tax Rate: Effective tax rate expected to be approximately 30% on normal taxable earnings.
• Dividends: Cash dividends of $0.44 per share were declared for Q1 2005.

Risks and Contingencies

• Legal Proceedings: The company faces ongoing sorbates litigation (appeal scheduled for May 2005) and approximately 3,000 pending asbestos claims. Management does not believe these will have a material adverse effect on overall financial condition but notes potential impacts on specific periods.
• Environmental: Reserves for environmental contingencies were $57 million. Estimated future expenditures range from $25 million to $44 million.
• Market Risks: Exposure to raw material costs, energy prices, and foreign currency exchange rates. The company uses hedging instruments to mitigate these risks.
• Subsequent Event: On April 21, 2005, the company completed the sale of its equity interest in Genencor International, Inc. for approximately $420 million in cash.

Investor Verification Checklist

• Genencor Sale Proceeds: Verify the impact of the $420 million Genencor sale (completed April 2005) on the balance sheet and liquidity in the subsequent quarter.
• Restructuring Reserves: Monitor the utilization of the $29 million remaining reserve for severance and site closure costs, with all separations expected within 12 months.
• Raw Material Hedging: Review the effectiveness of hedging strategies given the management's warning of continued volatility in raw material and energy costs.
• Capital Spending Execution: Track actual capital expenditures against the $340-$360 million guidance, specifically regarding the new IntegRex PET facility.
• Legal Outcomes: Monitor the outcome of the sorbates litigation appeal scheduled for May 2005 and the resolution of asbestos claims.